CARA Cara Therapeutics Inc

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, August 7, 2023, at 4:30 p.m. ET to report second quarter 2023 financial results and provide a corporate update.

To participate in the conference call, please register . Registrants will receive the dial-in numbers and a unique PIN.

A live audio webcast and archived replay of the call will be available under “Events & Presentations” in the Investors section of the Company’s website at .

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. For more information, visit and follow the company on , and .

MEDIA CONTACT:

Annie Spinetta

6 Degrees

973-768-2170

INVESTOR CONTACT:

Iris Francesconi, Ph.D.

Cara Therapeutics

203-406-3700

 



EN
24/07/2023

Underlying

CARACara Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cara Therapeutics Inc

 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics Announces Exploration of Strategic Alternatives

Cara Therapeutics Announces Exploration of Strategic Alternatives Piper Sandler & Co. to act as financial advisor STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that it has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and reviewing strategic alternatives. “We are committed to evaluating a range of strategic options to maximize value for our shareholders,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “As part of this effort, our Board of Director...

July 11, 2024 1 EN
 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evalu...

Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica – Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOU...

June 12, 2024 1 EN
 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics Reports First Quarter 2024 Financial Results

Cara Therapeutics Reports First Quarter 2024 Financial Results Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2024. “Our notalgia paresthetica (NP) pivotal clini...

May 13, 2024 1 EN
 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics to Announce First Quarter 2024 Financial Results on ...

Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024 STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close. The press release will be available under “Press Releases” in the Investors section of the Company’s website at . About Cara Therapeutics Cara Therapeu...

May 6, 2024 1 EN
 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Health...

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT. A webcast of the presentation can be accessed under "Events & Presentations" in the ...

April 2, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch